anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Over 268,000 children entered foster care in the United States during fiscal year 2019 despite the existence of Maltevidence-based programs (EBPs) that can successfully prevent child maltreatment. Evidence-informed decision-making (EIDM) can lead to the adoption of EBPs that are likely to be successfully implemented and result in the intended impacts. Despite the existence of EBPs to prevent child maltreatment, EBPs are underutilized in child welfare. Proposed study activities in this career development award respond to NIMH Objective 4.2.c by developing, refining, and piloting an implementation strategy to increase EIDM when decision makers are adopting EBPs to improve mental health and child welfare services. Activities leverage an unprecedented federal policy opportunity to prevent child maltreatment and test implementation decision support strategies in the real world: The Family First Prevention Services Act (FFPSA). FFPSA aims to prevent child maltreatment and foster care entries by providing federal funding to states for implementing EBPs that support child and parent mental health, reduce parental substance misuse, and improve parenting skills. This project engages decision makers from four states implementing FFPSA to extend the candidate's prior work developing an innovative EIDM tool to support EBP adoption: Optimizing Responses through Collaborative Assessments (ORCA). ORCA is based in multi-criteria decision analysis, which provides a structured approach to reach quality, evidence-informed group decisions. Given that group decisions with tools such as ORCA benefit from facilitation, this study will develop and test two facilitation modalities to accompany ORCA: automated (ORCA-A) and live (ORCA-L). In addition, a web-based platform to host the ORCA tool and the ORCA-A facilitation strategy will be developed with decision makers' input (Aim 1). The impact of ORCA-A and ORCA-L on quality of decision experiences, processes, and outcomes then will be tested (Aim 2). Implementation process quality for each EBP adopted with ORCA-A and ORCA-L will be monitored (Aim 3). To enhance her strong foundation in the implementation, decision, and systems sciences, the candidate, Dr. Gracelyn Cruden, will leverage these research activities and training activities to expand her skillset to include: leading implementation studies in service systems, employing a continuum of methods for engaging community members, leveraging interdisciplinary approaches for eliciting members' preferences, conducting advanced simulation model testing, and using advanced statistics for multilevel, longitudinal studies. Cruden will be mentored by an outstanding team led by Primary Mentor Dr. Lisa Saldana, who is accompanied by Mentors Dr. Jason Chapman, Dr. Lindsey Zimmerman, Dr. R. Christopher Sheldrick, Dr. Jonathan Purtle, and Consultants Dr. David Vanness, and Ms. Clare Anderson. Upon completion of these activities, Cruden will be equipped to lead an interdisciplinary research team that will support quality mental health and child welfare services by increasing decision makers' use of EIDM.
PURPOSE: A teeth whitening apparatus based on ultrasound wave and a teeth whitening method using the same are provided to implement a teeth whitening process without gum damages or teeth ache. CONSTITUTION: A teeth whitening apparatus includes a mouthpiece(120), a light emitting element(142), a ultrasound wave vibrating element(144), and a driving element. The mouthpiece is shaped in the form of a teeth-tray which is matched to the shape of teeth. The light emitting element and the ultrasound wave vibrating element are mounted at the mouthpiece. The driving element controls the light emitting element and the ultrasound wave vibrating element. The mouthpiece is based on silicon. The vibration frequency of the ultrasound wave vibrating element is in a range between 100 kHz and 10 MHz.
Influenza vaccines include hemagglutinin from at least one influenza A virus strain and at least one influenza B virus strain. They also include an oil-in-water emulsion adjuvant with submicron oil droplets, comprising squalene. In some embodiments the hemagglutinin concentration is >12[mu]g/ml per strain. In some embodiments the squalene concentration is <19mg/ml. In some embodiments the vaccine is mercury-free. In some embodiments the vaccine has a unit dose volume between 0.2-0.3mL. In some embodiments the squalene concentration is 9.75mg/mL or 4.88mg/mL. In some embodiments the vaccine includes antigens from two influenza A virus strains and two influenza B virus strains.
In the waiting list control group (WL), subjects will receive no treatment during 8 weeks. We will not interfere but we will monitor carefully through self-report. Then participants will be randomised to the two treatment groups.
The present invention relates to a traditional Chinese medicine preparation for treating colitis, which is prepared from ingredients, such as angelica, white peony alba, largehead atractylodes rhizome, ledebouriella root, milkvetch root, tangshen, tuckahoe, coptis, phellodendron bark, rhizoma anemarrhenae, peach seed, tuber of hyacinth bletilla, orange fruit, immature orange fruit, dried tangerine peel, green tangerine peel, rhubarb, bupleurum root, common aucklandia root, radix glycyrrhiza, poppy shell, common prism tuber, zedoray rhizome, red sage root, dahurian angelica, etc. Composing prescriptions of No. 1 to No. 5 are respectively used according to different disease types of colonitis. The present invention is suitable for treating various kinds of colonitis. The preparation has the advantages of scientific prescription, sufficient medicine source, economy and practicality, and can be prepared into powder, pills, pastes, aqueous agents and capsules for the original administration by patients, and the curing rate is above 90%.
The invention discloses rhodiola rosea qi-tonifying lung-heat clearing foot soaking powder and a preparing method thereof. The foot soaking powder is characterized by being prepared from rhodiola rosea, yerbadetajo herb, cymbopogon citratus, christina loosestrife, small centipeda herb, rabdosia serra, sambucus chinensis, mimosa pudica, green grapes, peach and plum. The preparing method includes steps of selecting, drying, powdering, adding spices, mixing, sterilizing and packaging. The foot soaking powder achieves healthcare effects through promoting blood circulation of a human body. Fragrance is increased through adding the spices. The spices are selected from natural compounds, are free of side effects or discomfort and capable of enhancing refreshing and consciousness restoring effects. Qi-tonifying and lung-heat clearing effects are achieved through soaking feet with traditional Chinese medicines, human body absorption capacity is improved, the human body is nourished with the traditional Chinese medicines, the qi-tonifying and lung-heat clearing effects are enhanced, and body physique is improved.
Depression is a debilitating illness affecting large numbers of young people. Psychotherapy approaches have shown some promise in teens, but few studies have examined these interventions when offered in a group format. The role of parents in treatment outcome has also received little attention.

In this study, children and adolescents ages 10 to 17 meeting criteria for clinical depression will participate in a 15-session group therapy (cognitive behavioral therapy or CBT) that teaches strategies for overcoming depressed mood. For half the participants, their parents will also participate in a parent group to help them better manage their depressed children and teens. We will randomly assign children to CBT with or without parental involvement. We hope to show that involving parents results in additional improvements in the children. We will also study factors that predict which children do best in treatment, and maintenance of gains at 6 month and 1 year follow-up. These findings will allow us to provide more effective treatments to depressed children and teens in the future.
BACKGROUND: To predict clinical important outcomes for colorectal liver metastases (CRLM) patients receiving colorectal resection with simultaneous liver resection by integrating demographic, clinical, laboratory, and genetic data.
METHODS: Random forest (RF) models were developed to predict postoperative complications and major complications (binary outcomes), as well as progression-free survival (PFS) and overall survival (OS) (time-to-event outcomes) of the CRLM patients based on data from two hospitals. The models were validated on an external dataset from an independent hospital. The clinical utility of the models was assessed via decision curve analyses (DCA).
RESULTS: There were 1067 patients included in survival prediction analyses and 1070 patients included in postoperative complication prediction analyses. The RF models provided an assessment of the model contributions of features for outcomes and suggested KRAS, BRAF, and MMR status were salient for the PFS or OS predictions. RF model of PFS showed that the Brier scores at 1-, 3-, and 5-year PFS were 0.213, 0.202 and 0.188; and the AUCs of 1-, 3- and 5-year PFS were 0.702, 0.720 and 0.743. RF model of OS revealed that Brier scores of 1-,3-, and 5-year OS were 0.040, 0.183 and 0.211; and the AUCs of 1-, 3- and 5-year OS were 0.737, 0.706 and 0.719. RF model for postoperative complication resulted in an AUC of 0.716 and a Brier score of 0.196. DCA curves clearly demonstrated that the RF models for these outcomes exhibited a superior net benefit across a wide range of threshold probabilities, signifying their favorable clinical utility. The RF models consistently exhibited robust performance in both internal cross-validation and external validation. The individualized risk profile predicted by the models closely aligned with the actual survival outcomes observed for the patients. A web-based tool (https://kanli.shinyapps.io/CRLMRF/) was provided to demonstrate the practical use of the prediction models for new patients in the clinical setting.
CONCLUSION: The predictive models and a web-based tool for personalized prediction demonstrated a moderate predictive performance and favorable clinical utilities on several key clinical outcomes of CRLM patients receiving simultaneous resection, which could facilitate the clinical decision-making and inform future interventions for CRLM patients.
NEW MATERIAL:A bioactive substance MP-A produced by a Staphylococcus aureus and having the following properties; Molecular weight: 1X10<4> dalton(SDS- PAGE method), Bioactivity: significantly high activity of lymphocyte transformation to human peripheral blood mononuclear cyte, production of interleukin-2, cytotoxicity and induction of IgG production, Solubility: soluble at >=pH4 and precipitate at <=pH3.5, Adsorptivity: adsorbed on strong ion exchanger. USE:A remedy of severe infectious diseases, virus infectious diseases, malignant tumor, etc. PREPARATION:For example, Staphylococcus aureus Cowan III type is cultured and the bacterium is crushed using an ultrasonic disintegrator followed by centrifugation for separation of the supernatant. The separated supernatant is ultrafiltrated for concentration and the resultant concentrated solution is dialyzed and subsequently subjected to the affinity chromatography method using a human IgG-bonded agarose column to collect the non-adsorbed fraction. To the obtained non-adsorbed fraction ammonium sulfate is added and the resultant precipitate is collected and redissolved. The obtained solution is fractionated using a strong ion exchange column for purification, thus obtaining the objective bioactive substance MP-A.
A multivalent immunoglobulin which comprises at least three linked antigen binding domains each of said domains being specific for a complementary site on a cytokine, (e.g. TBF- alpha , TNF- beta , an interleukin, an interferon, such as IFN- gamma , or/and a colony stimulating factor) and characteristically interacts with the cytokine to neutralise its biological activity. The multivalent immunoglobulins have surprisingly increased neutralising activity and are useful for therapeutic or prophylactic treatment of conditions involving undesirably elevated levels of cytokine. Preferably the multivalent immunoglobulin comprises from 4 to 20 antigen binding domains, which are especially of class IgG. The multivalent immunoglobulin may comprise recombinant immunoglobulin molecules and fragments thereof, and the antigen binding domains may be covalently or non-covalently linked. <IMAGE>
<P>PROBLEM TO BE SOLVED: To provide a novel system having no shortcoming of an existing bleaching method for dying keratin materials, in particular human keratin fibers, especially dark hair.  <P>SOLUTION: A hemicyanine styryl thiol or disulfide dye is used for dyeing keratin materials. The dye composition comprising the hemicyanine styryl chromophore thiol or disulfide dye is used for a dyeing method with a lightening effect on keratin materials, in particular keratin fibers, especially human keratin fibers such as the hair. Similarly, a novel hemicyanine styryl chromophore thiol dye and its use in lightening keratin materials are also provided. The composition allows coloring with a durable and visible lightening effect on dark keratin fibers especially.  <P>COPYRIGHT: (C)2009,JPO&INPIT
BACKGROUND: Patients with multiple long-term conditions requires understanding the existing care models to address their complex and multifaceted health needs. However, current literature lacks a comprehensive overview of the essential components, impacts, challenges, and facilitators of these care models, prompting this scoping review.
METHODS: A scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis Extension for Scoping Reviews guideline. Our search encompassed articles from PubMed, Web of Science, EMBASE, SCOPUS, and Google Scholar. The World Health Organization's health system framework was utilized to synthesis the findings. This framework comprises six building blocks (service delivery, health workforce, health information systems, access to essential medicines, financing, and leadership/governance) and eight key characteristics of good service delivery models (access, coverage, quality, safety, improved health, responsiveness, social and financial risk protection, and improved efficiency). Findings were synthesized qualitatively to identify components, impacts, barriers, and facilitators of care models.
RESULTS: A care model represents various collective interventions in the healthcare delivery aimed at achieving desired outcomes. The names of these care models are derived from core activities or major responsibilities, involved healthcare teams, diseases conditions, eligible clients, purposes, and care settings. Notable care models include the Integrated, Collaborative, Integrated-Collaborative, Guided, Nurse-led, Geriatric, and Chronic care models, as well as All-inclusive Care Model for the Elderly, IMPACT clinic, and Geriatric Patient-Aligned Care Teams (GeriPACT). Other care models (include Care Management Plus, Value Stream Mapping, Preventive Home Visits, Transition Care, Self-Management, and Care Coordination) have supplemented the main ones. Care models improved quality of care (such as access, patient-centeredness, timeliness, safety, efficiency), cost of care, and quality of life for patients that were facilitated by presence of shared mission, system and function integration, availability of resources, and supportive tools.
CONCLUSIONS: Care models were implemented for the purpose of enhancing quality of care, health outcomes, cost efficiency, and patient satisfaction by considering careful recruitment of eligible clients, appropriate selection of service delivery settings, and robust organizational arrangements involving leadership roles, healthcare teams, financial support, and health information systems. The distinct team compositions and their roles in service provision processes differentiate care models.
Status epilepticus (SE) is a medical and neurologic emergency that may lead to permanent brain damage, morbidity, or death. Animal models of SE are particularly important to study the pathophysiology of SE and mechanisms of SE resistance to antiseizure medications with the aim to develop new, more effective treatments. In addition to rodents (rats or mice), larger mammalian species such as dogs, pigs, and nonhuman primates are used. This short review describes and discusses the value and limitations of the most frequently used mammalian models of SE. Issues that are discussed include (1) differences between chemical and electrical SE models; (2) the role of genetic background and environment on SE in rodents; (3) the use of rodent models (a) to study the pathophysiology of SE and mechanisms of SE resistance; (b) to study developmental aspects of SE; (c) to study the efficacy of new treatments, including drug combinations, for refractory SE; (d) to study the long-term consequences of SE and identify biomarkers; (e) to develop treatments that prevent or modify epilepsy; (e) to study the pharmacology of spontaneous seizures; (4) the limitations of animal models of induced SE; and (5) the advantages (and limitations) of naturally (spontaneously) occurring SE in epileptic dogs and nonhuman primates. Overall, mammalian models of SE have significantly increased our understanding of the pathophysiology and drug resistance of SE and identified potential targets for new, more effective treatments. This paper was presented at the 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in April 2024.
There is provided a method for determining a regional rupture potential (RRP) indicative of the state of local weakening of a blood vessel based on parameters that correlate with the expansion and local weakening of the vessel. The method comprises: receiving a plurality of images of the blood vessel into a multiphase stack. A geometrical model of the lumen and the outer wall of the vessel are generated and smoothed to obtain a volume mesh and surface mesh respectively. An ILT thickness distribution, a local deformation at each phase and a wall strain distribution indicative of a maximal principal strain at the outer wall are determined. Blood flow values in the lumen are obtained and a wall shear stress distribution indicative of wall shear disturbances in the lumen is calculated. The RRP is determined based on the ILT thickness distribution, the wall shear stress, and the wall strain.
Talactoferrin alfa (talactoferrin or TLF, also known as recombinant human lactoferrin, rhLF or talactoferrinum alfa) is a recombinant version of the glycoprotein expressed in and purified from Aspergillus niger var. awamori. Talactoferrin is structurally and functionally similar to native human lactoferrin. The structural equivalence of talactoferrin to native human lactoferrin has been demonstrated by a comparison of the 3-dimensional structure, molecular weight, biological activity and other physicochemical properties, and is known to differ only in the nature of glycosylation.
BACKGROUND: Chemotherapy is commonly used in metastatic breast cancer (MBC) to prolong life and improve quality of life (QoL). The optimal dosing and sequencing beyond the second line of treatment are unknown and pose a risk of overtreatment. Continuous low oral doses of metronomic chemotherapy using capecitabine 500 mg three times daily and cyclophosphamide 50 mg once daily (MCT-CX) may be an effective and tolerable treatment option for patients with MBC.
METHODS: In this open-label, single-arm single-centre phase II trial patients with MBC received MCT-CX until disease progression or unacceptable toxicity. The primary endpoint was the clinical benefit rate (CBR), defined as the proportion of participants with a best overall response of complete (CR) or partial response (PR) at any time, or stable disease (SD) for ≥24 weeks according to radiological evaluation. Toxicity was assessed according to the Common Toxicity Criteria v 4.0. QoL was assessed with the EORTC-30 questionnaire.
RESULTS: In total, 40 patients were included. Most participants (72 %) presented with visceral disease and received MCT-CX beyond the second line (58 %). The CBR was 45 % (8 PR and 10 SD ≥ 24 weeks). Toxicities were low grade with hand-foot syndrome being the most common. There was no significant change in QoL over the first 24 weeks.
CONCLUSION: MCT-CX is a plausible treatment option in far advanced breast cancer, with almost half of trial participants responding to treatment without QoL impairments.
Dorzolamide hydrochloride and timolol maleate ophthalmic solution, USP is the combination of a topical carbonic anhydrase inhibitor and a topical beta-adrenergic receptor blocking agent. 

Dorzolamide hydrochloride, USP is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide monohydrochloride. Dorzolamide hydrochloride, USP is optically active. The specific rotation is: 

Its empirical formula is C10H16N2O4S3•HCl and its structural formula is: 

Dorzolamide hydrochloride, USP has a molecular weight of 360.90. It is a white to off-white, crystalline powder, which is soluble in water and slightly soluble in methanol and ethanol. 

Timolol maleate, USP is described chemically as: (-)-1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate, USP possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate, USP is: 

Its molecular formula is C13H24N4O3S•C4H4O4 and its structural formula is: 

Timolol maleate, USP has a molecular weight of 432.49. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.

Dorzolamide hydrochloride and timolol maleate ophthalmic solution is supplied as a sterile, clear, colorless to nearly colorless, isotonic, buffered, slightly viscous, aqueous solution. The pH of the solution is approximately 5.65, and the osmolarity is 242 to 323 mOsM. Each mL of dorzolamide hydrochloride and timolol maleate ophthalmic solution contains 20 mg dorzolamide (equivalent to 22.26 mg of dorzolamide hydrochloride) and 5 mg timolol (equivalent to 6.83 mg timolol maleate). Inactive ingredients are hydroxyethyl cellulose, mannitol, sodium citrate dihydrate, sodium hydroxide, and water for injection. Benzalkonium chloride 0.0075% is added as a preservative.
Several person variables predate injury or pain onset that increase the probability of maladjustment to pain and opioid misuse. The aim of this study was to evaluate the role of 2 diathesis variables (impulsiveness and anxiety sensitivity [AS]) in the adjustment of individuals with chronic noncancer pain and opioid misuse. The sample comprised 187 individuals with chronic noncancer pain. The hypothetical model was tested using correlation and structural equation modeling analyses. The results show a significant association between impulsiveness and AS and all the maladjustment variables, and between impulsiveness and AS and opioid misuse and craving. However, although the correlation analysis showed a significant association between adjustment to pain and opioid misuse, the structural equation modeling analysis showed a nonsignificant association between them (as latent variables). The findings support the hypothesis that both impulsiveness and AS are vulnerability factors for maladaptive adjustment to chronic pain and opioid misuse. PERSPECTIVE: This article adds to the empirical literature by including AS and impulsiveness as antecedent variables in a model of dual vulnerability to chronic pain maladjustment and opioid misuse. The findings suggest the potential utility of assessing both factors in individuals in the first stages of chronic pain.